Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.
Genetic: RNA analysis
Genetic: gene expression analysis
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma|
- Serum miR-206 as a biomarker for RMS [ Designated as safety issue: No ]
|Study Start Date:||September 2011|
|Estimated Primary Completion Date:||January 2100 (Final data collection date for primary outcome measure)|
- Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS).
OUTLINE: Archived serum samples are analyzed for miR-206 expression.
PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01433237
|Principal Investigator:||Hajime Hosoi, MD||Kyoto Prefectural University of Medicine|